Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 4, 2009, Pages 447-455

  Li, S ^a   Stuart, L ^b   Zhang, Y ^b   Meduri, G U ^b,c   Umberger, R ^c   Yates, C R ^b  

^a IQVIA   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Pharmacogenetics; Platelet activating factor acetylhydrolase; Single nucleotide polymorphism (SNP)

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ARGININE; METHYLPREDNISOLONE; PLACEBO;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ALLELES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, ADULT; SURVIVORS;

EID: 67651247761     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.01014.x     Document Type: Article

References (52)

1. Downey GP, Dong Q, Kruger J, Dedhar S, Cherapanov V (1999) Regulation of neutrophil activation in acute lung injury. Chest, 116, 46S 54S.
2. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM (1992) High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. The American Review of Respiratory Disease, 145, 1016 1022.
3. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP (2005) Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation, 12, 321 338.
4. Meduri GU, Yates CR (2004) Systemic inflammation-associated glucocorticoid resistance and outcome of ARDS. Annals of the New York Academy of Sciences, 1024, 24 53.
5. Parsons PE, Eisner MD, Thompson BT, Matthay MA, Ancukiewicz M, Bernard GR, Wheeler AP (2005) Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Critical Care Medicine, 33, 1 6. discussion 230-232.
6. Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. The American Review of Respiratory Disease, 138, 720 723.
7. Bone RC, Maunder R, Slotman G, Silverman H, Hyers TM, Kerstein MD, Ursprung JJ (1989) An early test of survival in patients with the adult respiratory distress syndrome. The PaO2/FIo2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. Chest, 96, 849 851.
8. Bernard GR, Luce JM, Sprung CL et al. (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. New England Journal of Medicine, 317, 1565 1570.
9. Meduri GU (1997) Host defense response and outcome in ARDS. Chest, 112, 1154 1158.
10. Shimizu T, Honda Z, Nakamura M, Bito H, Izumi T (1992) Platelet-activating factor receptor and signal transduction. Biochemical Pharmacology, 44, 1001 1008.
11. Miotla JM, Jeffery PK, Hellewell PG (1998) Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. American Journal of Respiratory Cell and Molecular Biology, 18, 197 204.
12. Nagase T, Ishii S, Kume K, Uozumi N, Izumi T, Ouchi Y, Shimizu T (1999) Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. Journal of Clinical Investigation, 104, 1071 1076.
13. Nakos G, Kitsiouli EI, Tsangaris I, Lekka ME (1998) Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Medicine, 24, 296 303.
14. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM (1997) Platelet-activating factor acetylhydrolases 67. Journal of Biological Chemistry, 272, 17895 17898.
15. Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM (1989) Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proceedings of the National Academy Sciences of the United States of America, 86, 2393 2397.
16. Tjoelker LW, Wilder C, Eberhardt C et al. (1995) Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature, 374, 549 553.
17. Graham RM, Stephens CJ, Silvester W, Leong LL, Sturm MJ, Taylor RR (1994) Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Critical Care Medicine, 22, 204 212.
18. Stafforini DM, Satoh K, Atkinson DL et al. (1996) Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. Journal of Clinical Investigation, 97, 2784 2791.
19. Kruse S, Mao XQ, Heinzmann A et al. (2000) The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. American Journal of Human Genetics, 66, 1522 1530.
20. Yamada Y, Yokota M (1997) Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281 - >Arg mutation. Biochemical and Biophysical Research Communications, 236, 772 775.
21. Hiramoto M, Yoshida H, Imaizumi T, Yoshimizu N, Satoh K (1997) A mutation in plasma platelet-activating factor acetylhydrolase (Val279 - >Phe) is a genetic risk factor for stroke. Stroke, 28, 2417 2420.
22. Yamada Y, Ichihara S, Fujimura T, Yokota M (1998) Identification of the G994 - > T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism, 47, 177 181.
23. Claus RA, Russwurm S, Dohrn B, Bauer M, Losche W (2005) Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Critical Care Medicine, 33, 1416 1419.
24. Meduri GU, Golden E, Freire AX et al. (2007) Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest, 131, 954 963.
25. Bernard GR, Artigas A, Brigham KL et al. (1994) Report of the American-European consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. consensus committee. Journal of Critical Care, 9, 72 81.
26. Petty TL (1996) Acute respiratory distress syndrome: consensus, definitions, and future directions. Critical Care Medicine, 24, 555 556.
27. Song P, Li S, Meibohm B, Gaber AO, Honaker MR, Kotb M, Yates CR (2002) Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. AAPS PharmSci, 4, E29.
28. Kitsiouli EI, Nakos G, Lekka ME (1999) Differential determination of phospholipase A(2) and PAF- acetylhydrolase in biological fluids using fluorescent substrates. Journal of Lipid Research, 40, 2346 2356.
29. Guo SW, Thompson EA (1992) Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics, 48, 361 372.
30. Schneider S, Roessli D, Excoffier L (2000) Arlequin: A Software for population genetics data analysis. Version 2.000 : Genetics and Biometry Laboratory, Department of Anthropology, University of Geneva. Available at: http://lgb.unige.ch/arlequin/software/2.000/doc/faq/faqlist. htm#How%20do%201%20cite%20Arlequin (accessed 4 December 2008).
31. Knaus WA, Wagner DP, Draper EA et al. (1991) The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest, 100, 1619 1636.
32. Chollet-Martin S, Jourdain B, Gibert C, Elbim C, Chastre J, Gougerot-Pocidalo MA (1996) Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. American Journal of Respiratory and Critical Care Medicine, 154, 594 601.
33. Folch E, Salas A, Panes J et al. (1999) Role of P-selectin and ICAM-1 in pancreatitis-induced lung inflammation in rats: significance of oxidative stress. Annals of Surgery, 230, 792 798. discussion 798-799.
34. Wagner JG, Roth RA (2000) Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacological Reviews, 52, 349 374.
35. Maruoka S, Hashimoto S, Gon Y, Takeshita I, Horie T (2000) PAF-induced RANTES production by human airway smooth muscle cells requires both p38 MAP kinase and Erk. American Journal of Respiratory and Critical Care Medicine, 161, 922 929.
36. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM (1991) Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. Journal of Biological Chemistry, 266, 11095 11103.
37. Asano K, Okamoto S, Fukunaga K et al. (1999) Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochemical and Biophysical Research Communications, 261, 511 514.
38. Bulger EM, Gourlay D, Cuschieri J, Jelacic S, Staudenmeyer K, Garcia I, Maier RV (2003) Platelet-activating factor acetylhydrolase inhibits alveolar macrophage activation in vivo. Shock, 20, 17 22.
39. Grypioti AD, Mykoniatis M, Demopoulos CA, Kostopanagiotou G (2007) Recombinant platelet-activating factor-acetylhydrolase attenuates paracetamol-induced liver oxidative stress, injury, and regeneration. Digestive Diseases and Sciences, 52, 192 199.
40. Grypioti AD, Kostopanagiotou G, Mykoniatis M (2007) Platelet-activating factor inactivator (rPAF-AH) enhances liver's recovery after paracetamol intoxication. Digestive Diseases and Sciences, 63, 1054 1062.
41. Gomes RN, Bozza FA, Amancio RT et al. (2006) Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock, 26, 41 49.
42. Schuster DP, Metzler M, Opal S et al. (2003) Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Critical Care Medicine, 31, 1612 1619.
43. Opal S, Laterre PF, Abraham E et al. (2004) Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Critical Care Medicine, 32, 332 341.
44. Stafforini DM (2001) PAF acetylhydrolase gene polymorphisms and asthma severity. Pharmacogenomics, 2, 163 175.
45. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM (2002) The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Critical Care Medicine, 30, S294 S301.
46. Stafforini DM, Tjoelker LW, McCormick SP et al. (1999) Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. Journal of Biological Chemistry, 274, 7018 7024.
47. Miwa M, Miyake T, Yamanaka T et al. (1988) Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. Journal of Clinical Investigation, 82, 1983 1991.
48. Trimoreau F, Francois B, Desachy A, Besse A, Vignon P, Denizot Y (2000) Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome. Mediators of Inflammation, 9, 197 200.
49. Unno N, Nakamura T, Kaneko H et al. (2000) Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan. Journal of Vascular Surgery, 32, 263 267.
50. Serebruany VL, Gurbel PA, Murugesan SR, Lowry DR, Sturm E, Svetlov SI (1998) Depressed plasma platelet-activating factor acetylhydrolase in patients presenting with acute myocardial infarction. Cardiology, 90, 127 130.
51. Nathan N, Denizot Y (1998) Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock, 9, 231 232.
52. Partrick DA, Moore EE, Moore FA, Biffl WL, Barnett CC (1997) Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. Shock, 7, 170 174.